Table 4.
Treatment initiation and outcomes by year of follow-up among patients with chronic hepatitis C virus (HCV) infection at five Federally Qualified Health Centers, Philadelphia PA, 2012–2016
| Year of follow-up | Diagnosed HCV RNA positive during year of follow-up* | Treated within one calendar year of RNA positive test | Treated >one year after RNA positive test | Untreated as of June 2017 | Cumulative HCV RNA positive patients by year of follow-up¶ | Initiated treatment during year of follow-up | Treatment completed | Assessed for sustained virologic response** | Achieved sustained virologic response |
|---|---|---|---|---|---|---|---|---|---|
| N | n (%) | n (%) | n (%) | N | n (%) | n (%) | n (%) | n (%) | |
| 10/2012 – 6/2013 | 112 | 6 (5.4) | 13 (11.6) | 92 (82.1) | 112 | 4 (4.4) | 4(100.0) | 4(100.0) | 3 (75.0) |
| 7/2013–6/2014 | 273 | 11 (4.0) | 26 (9.5) | 236 (86.4) | 382 | 9 (2.4) | 9 (100.0) | 7 (77.8) | 6 (85.7) |
| 7/2014–6/2015 | 235 | 21 (8.9) | 20 (8.5) | 194 (82.6) | 608 | 17 (2.8) | 15 (88.2) | 14 (93.3) | 12 (85.7) |
| 7/2015–6/2016 | 265 | 34 (12.8) | 2 (0.8)† | 230 (86.7)† | 857 | 64 (7.5) | 54 (84.4) | 42 (77.8) | 39 (92.9) |
| 7/2016–6/2017 | Not included | -- | -- | -- | 795 | 41 (5.2) | 26 (90.0)‖ | 12 (46.2) | 12 (100.0) |
| Total | 885 | 72 (8.1) | 61 (6.9) | 752 (85.0) | 885 | 135 (15.3)§ | 108 (87.8)# | 79 (73.1) | 72 (91.1) |
First positive test at the health center during the study period; patients may have had prior testing at the health center or with an outside provider.
Data collection ended June 2017, thus ascertainment of treatment initiation among patients tested in this period is incomplete and represents a minimum estimate.
Cumulative number of known HCV RNA positive patients without prior sustained virologic response during year of follow-up based on first positive HCV RNA test at the health center during the study period; patients may have had prior testing at the health center or with an outside provider.
Total number of patients who initiated treatment during the designated follow-up year (n=135) includes two patients who failed treatment but were retreated during the study period.
Denominator (n=29) adjusted to exclude 12 (29.3%) patients treated in that year who remained on therapy as of July 2017 and could not be evaluated for completion.
Denominator (n=123) adjusted to exclude 12 (8.9%) patients treated in that year who remained on therapy as of July 2017 and could not be evaluated for completion.
Excluding patients lost to follow-up and/or pending laboratory evaluation of treatment outcome. During the final period 12 (46%) patients who completed treatment in that year had not yet reached 12 weeks post-completion for SVR evaluation by June 2017.